<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00990028</url>
  </required_header>
  <id_info>
    <org_study_id>28-09ROHI</org_study_id>
    <nct_id>NCT00990028</nct_id>
  </id_info>
  <brief_title>Effect of Rosuvastatin on Cytokines After Traumatic Brain Injury</brief_title>
  <official_title>Effect of Rosuvastatin on Immunological Markers After Traumatic Brain Injury: Clinical Randomized Double Blind Study Phase 2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidad Autonoma de San Luis Potosí</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Central &quot;Dr. Ignacio Morones Prieto&quot;</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Universidad Autonoma de San Luis Potosí</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether rosuvastatin could alter the immunological
      response after head injury by modulating TNF-alpha,IL6,IL-1.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The head injury is a frequent problem of health, which produces high morbid-mortality. Today
      is the main cause of death and disability between 18 and 40 years. In addition it originates
      expensive expenses in health care systems.

      Head injury produces damage by primary mechanisms related to impact, then by biochemical ways
      which are activated and they carry to secondary damage. Many studies have been conducted for
      explaining secondary injury, the majority conclude there is a kind of ischemic lesion related
      maybe with changes in cerebral flow and metabolism. All these changes are associated to a
      immunological response. Up to now some drugs are directed to modulate the immunological
      system, although many of them have been ineffective.

      Statins o inhibitors of HMG CoA reductase are drugs used in dyslipidemia, frequently for
      reduction in LDL. Experimental and clinical studies in stroke have shown improvement in
      outcome. The toxicity related to statin is myopathy and hepatopathy, both with low incidence
      without fatal cases. Rosuvastatin has been postulated be the most powerful with longest life
      and toxicity similar to another statins. Many studies have suggested an important
      immunomodulator effect after statins administration, The investigators have previously
      demonstrated the possible effect of statin on amnesia and disorientation improvement with
      patients who suffered a moderated head injury (Glasgow 9-13). The aim of this new study is to
      analyze the possible immunomodulator role of statins on head injury.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasmatic levels of cytokines (IL-1B, IL-6, TNF-alfa) (pg/dL)</measure>
    <time_frame>Day 3</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Functional outcome by Disability Rating Scale</measure>
    <time_frame>after 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change of lesions on CT scan</measure>
    <time_frame>72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of CK, AST, ALT</measure>
    <time_frame>3rd and 7th day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amnesia time using GOAT Score</measure>
    <time_frame>in-patient follow-up, after 3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Head Injury</condition>
  <arm_group>
    <arm_group_label>Rosuvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 mg oral during 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>20 mg oral, for 10 days</description>
    <arm_group_label>Rosuvastatin</arm_group_label>
    <other_name>Crestor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>20 mg vehicle</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Man or woman &gt; 16 and &lt; 60 years old with HI less 24 hours in progression and Glasgow
             between &lt; 13

          -  Acceptance of family to participate (first grade)

        Exclusion Criteria:

          -  Previous head injury with severe disability

          -  History of neurological or psychiatric disease with severe disability

          -  Administration 24 hrs previous of: fibrates, niacin, ciclosporin, azoles, macrolides,
             inhibitors of protease, nefazodone, verapamil, diltiazem,amiodarone

          -  Very poor possibilities for survival

          -  Use of Administration of THAM, mannitol, barbiturates, corticosteroids, scavengers of
             free radicals, inhibitors of lipidic peroxidation, indometacin, calcium antagonist,
             antagonists of neurotransmitters before randomization

          -  isolated lesions in brain stem

          -  Allergy to the drug

          -  Hepatopathy or myopathy (or) history of this, or clinical data of hepatic disease

          -  Management previous in other Hospital

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Gordillo-Moscoso, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Clinical Epidemiology UASLP</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martin Sanchez-Aguilar, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical epidemiology UASLP</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Central &quot;Dr. Ignacio Morones Prieto&quot;</name>
      <address>
        <city>San Luis Potosi</city>
        <zip>78420</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <reference>
    <citation>Tapia-Perez H, Sanchez-Aguilar M, Torres-Corzo J, Rodriguez-Leyva I, Herrera-Gonzalez LB. [Statins and brain protection mechanisms]. Rev Neurol. 2007 Sep 16-30;45(6):359-64. Review. Spanish.</citation>
    <PMID>17899518</PMID>
  </reference>
  <reference>
    <citation>Tapia-Perez J, Sanchez-Aguilar M, Torres-Corzo JG, Gordillo-Moscoso A, Martinez-Perez P, Madeville P, de la Cruz-Mendoza E, Chalita-Williams J. Effect of rosuvastatin on amnesia and disorientation after traumatic brain injury (NCT003229758). J Neurotrauma. 2008 Aug;25(8):1011-7. doi: 10.1089/neu.2008.0554.</citation>
    <PMID>18690806</PMID>
  </reference>
  <reference>
    <citation>Tapia-Perez H, Sanchez-Aguilar M, Torres-Corzo JG, Rodriguez-Leyva I, Gonzalez-Aguirre D, Gordillo-Moscoso A, Chalita-Williams C. Use of statins for the treatment of spontaneous intracerebral hemorrhage: results of a pilot study. Cent Eur Neurosurg. 2009 Feb;70(1):15-20. doi: 10.1055/s-0028-1082064. Epub 2009 Feb 5.</citation>
    <PMID>19197830</PMID>
  </reference>
  <reference>
    <citation>Tapia-Pérez JH, Sanchez-Aguilar M, Schneider T. The role of statins in neurosurgery. Neurosurg Rev. 2010 Jul;33(3):259-70; discussion 270. doi: 10.1007/s10143-010-0259-4. Epub 2010 Apr 29. Review.</citation>
    <PMID>20429022</PMID>
  </reference>
  <verification_date>October 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 5, 2009</study_first_submitted>
  <study_first_submitted_qc>October 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2009</study_first_posted>
  <last_update_submitted>October 5, 2011</last_update_submitted>
  <last_update_submitted_qc>October 5, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 6, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr. Martin Sanchez</name_title>
    <organization>Clinical Epidemiology UASLP</organization>
  </responsible_party>
  <keyword>moderate head injury</keyword>
  <keyword>rosuvastatin</keyword>
  <keyword>statin</keyword>
  <keyword>amnesia</keyword>
  <keyword>orientation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
    <mesh_term>Craniocerebral Trauma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

